The changing therapeutic armamentarium for patients with type 1 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 23, Issue 2, 2016, Pages 106-110

  Comee, Morgan ^a   Peters, Anne ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Glucagon like peptide 1 receptor agonist; Sodium glucose co Transporter 2 inhibitor; Type 1 Diabetes

Indexed keywords

EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; KETONE BODY; LIRAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); DIABETIC KETOACIDOSIS; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GLYCEMIC INDEX; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOGENESIS; OFF LABEL DRUG USE; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; WEIGHT REDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR TARGETED THERAPY; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84959917974     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000239     Document Type: Review

References (22)

1. The top 10 causes of death [Internet]. 2013. http://who.int/mediacentre/factsheets/fs310/en/. [Accessed 15 December 2015]
2. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose cotransporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs 2015; 23:875-882.
3. Writing team for the diabetes control and complications trial/epidemiology of diabetes interventions and complications research group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003; 22:2159-2167.
4. Hypoglycemia in the diabetes control and complications trial. The diabetes control and complication trial research group. Diabetes 1992; 46:271-286.
5. Helmsley Trust. http://helmsleytrust.org/contact-us. [Accessed 12 February 2015]
6. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 2005; 353:2643-2653.
7. Luddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE: A global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycemia from the European cohort. Diabetes Obes Metab 2007; 9:428-434.
8. Donnelly LA, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-Treated type 2 diabetes: A population-based study. Diabet Med 2005; 22:749-755.
9. Munir KM, Davis SN. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Exper opin Pharmacother 2015; 16:2331-2341.
10. Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on insulin in patients with type I diabetes. Diabetes Care 2015; 38:2258-2265.
11. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: A 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes obes metab 2015; 17:928-935.
12. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014; 37:1480-1483.
13. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitors, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015; 38:1181-1188.
14. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38:1687-1693.
15. FDA Medwatch [Internet]. September 2015. http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm. [Accessed 15 December 2015]
16. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38:420-428.
17. Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med 2015; 373:2117-2128.
18. Sarkar G, Alattar M, Brown RJ, et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014; 37:666-670.
19. Ghazi R, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care 2014; 37:210-216.
20. Frandsen CS, Dejgaard TF, Holst JJ, et al. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: A randomized, placebo-controlled, double-blinded parallel study. Diabetes Care 2015; 38:2250-2257.
21. Dejgaard. Frandsen CS, Knop FK, et al. Efficacy and safety of liraglutide added to insulin in type 1 diabetes: The LIRA-1 trial. Diabetes 2015; 64(suppl 1); Abstract 277-OR.
22. Novo Nordisk Company Announcement [Internet]. August 2015. www.novonordisk. com. [Accessed 15 December 2015]